FANGZHOU JIANKE
Listing Date | 2024/07/09 |
Listing Price | 8.180 |
- Subscription Rate16.63x
- Guarantee One Lot Size4 lot
- One Lot Success Rate40.04%
Listing Date | 2024/07/09 |
Listing Price | 8.180 |
Fangzhou Inc. commenced its business with a focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. Leveraging its chronic disease management platform, it is dedicated to providing tailored medical care and precision medicine for a growing population of chronic disease patients, with a view towards extending its services to a wider range of disease areas.
--
To address the needs of patients with chronic diseases for convenient and accessible medical care services, the Group provides comprehensive medical services and online retail pharmacy services through its Jianke Platform. In addition, a significant portion of its revenue was attributable to the sales of pharmaceutical and other healthcare products with service package.
--
The Group is the largest online chronic disease management platform in China in terms of average MAU in 2023, according to CIC. It ranked first in terms of prescription drug GMV in the online to-consumer CDM market in China.
--
Customers for the Group’s comprehensive medical services and online retail pharmacy services are mainly individual users. For its customized content and marketing solutions, its customers are mainly pharmaceutical companies.
Market | Hong Kong (Main Board) |
Business Nature | Health Care |
Major Business Area | China |
Board Lot | 500 |
No. of Offer Shares | 23.80M shares |
No. of International Offer Shares | 16.66M shares |
No. of HK Offer Shares | 7.14M shares |
Offer Price | $7.60 - $8.36 |
Stock Code | 6086 |
Sponsor(s) | Citigroup Global Markets Asia Limited, ABCI Capital Limited |
Underwriter(s) | Citigroup Global Markets Asia Limited, ABCI Securities Company Limited, Essence International Securities (Hong Kong) Limited, ICBC International Securities Limited, China Galaxy International Securities (Hong Kong) Co., Limited, China Everbright Securities (HK) Limited, China Merchants Securities (HK) Co., Limited, Citrus Securities Limited, CMB International Capital Limited, Fosun International Securities Limited, GF Securities (Hong Kong) Brokerage Limited, Huatai Financial Holdings (Hong Kong) Limited, Long Bridge HK Limited, Shenwan Hongyuan Securities (H.K.) Limited, Zhongtai International Securities Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Victory Securities Company Limited, Yue Xiu Securities Company Limited |
Application Period | Jun 28 (Fri) - noon, Jul 04 (Thu) |
Price Determination Date | Jul 05 (Fri) |
Result Announcement Date | On or before Jul 08 (Mon) |
Result Announcement Date | On or before Jul 08 (Mon) |
Result Announcement Date | On or before Jul 09 (Tue) |
Dealings in Shares commence on | Jul 09, 2024. (Tue) |
Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
% of total shares reallocated to HK Offer | 30% | 40% | 50% |
Offer Price | $7.60 - $8.36 |
Capitalization | 10.19B - 11.20B |
NAV / share ($) | $0.11 - $0.12 (Unaudited pro forma adj NAV / share) |
Assuming the offer price being at HKD 7.98, the net proceeds raised would be HKD 63.07M, of which |
67.4% : Used for business expansion in the next three to five years |
16% : Used for research and development activities in the next five year |
11.6% : Used for potential investments and acquisitions or strategic alliances with of the online chronic disease management industry |
5% : Working capital |
09/07/2024 16:08 |
{New Stock}FANGZHOU JIANKE ends down 44.62% at HK$4.53 |
09/07/2024 09:20 |
{New Stock}FANGZHOU JIANKE opens down 42.79% at HK$4.68 |
08/07/2024 18:35 |
{New Stock}FANGZHOU JIANKE ends down 38.51% on grey market |
08/07/2024 16:20 |
{New Stock}FANGZHOU JIANKE(06086) down 31.79% on grey market |
Prospectus | Chinese Version | English Version |
Remark: | The above information is referenced from the prospectus. |
All data is calculated from the non- exercise rights(if applicable). |
Currency | : |
Listing Price | : |
Board Lot | : |
Admission Fee* |
: |
Subscribing Lot | : |
Subscribing Fee | : |
Subscribing Amount | : |